6Q4I
CDK2 in complex with FragLite35
Summary for 6Q4I
Entry DOI | 10.2210/pdb6q4i/pdb |
Descriptor | Cyclin-dependent kinase 2, DIMETHYL SULFOXIDE, 2-[4-[(2-oxidanylidene-3~{H}-pyridin-4-yl)oxy]phenyl]ethanoic acid, ... (4 entities in total) |
Functional Keywords | fragment, fraglite, cdk2, inhibitor, cell cycle |
Biological source | Homo sapiens (Human) |
Total number of polymer chains | 1 |
Total formula weight | 35140.82 |
Authors | Wood, D.J.,Martin, M.P.,Noble, M.E.M. (deposition date: 2018-12-05, release date: 2019-03-20, Last modification date: 2024-01-24) |
Primary citation | Wood, D.J.,Lopez-Fernandez, J.D.,Knight, L.E.,Al-Khawaldeh, I.,Gai, C.,Lin, S.,Martin, M.P.,Miller, D.C.,Cano, C.,Endicott, J.A.,Hardcastle, I.R.,Noble, M.E.M.,Waring, M.J. FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. J.Med.Chem., 62:3741-3752, 2019 Cited by PubMed: 30860382DOI: 10.1021/acs.jmedchem.9b00304 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.11 Å) |
Structure validation
Download full validation report